Patho Pharm II Exam III

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/130

encourage image

There's no tags or description

Looks like no tags are added yet.

131 Terms

1
New cards

Disorders of Decreased Cell Count

RBCs: anemias

WBCs: leukopenia/neutropenia

Platelets: thrombocytopenia

2
New cards

Disorders of Increased/Abnormal Cell Proliferation

RBCs: polycythemia vera

WBCs: leukemia

Platelets: thrombocythemia

3
New cards

Anemia

Causes:

  • blood loss (GI, GU)

  • RBC destruction (hemolysis)

  • decreased RBC production

S/S:

  • fatigue

  • pallor

  • dizziness

  • shortness of breath

Classification:

  • Microcytic (small RBCs)

    • iron deficiency anemia (IDA)

    • thalassemia

  • Normocytic (normal RBC size)

    • aplastic anemia

    • hemolytic anemias (ex. sickle cell)

  • Macrocytic (large RBCs)

    • vitamin B12 deficiency

    • folate deficiency


4
New cards

Anemia Labs

CBC: complete blood count

  • RBC (million/μL)

    • Men: 4.5-5.5

    • Women: 4.0-5.0

  • Hemoglobin (Hgb) (g/dL)

    • Men: 14-18

    • Women: 12-16

  • Hematocrit (Hct) (%)

    • Men: 40-54

    • Women: 36-46

MCV: mean corpuscular volume

- RBC size (fL); normal 80-100 fL

  • microcytic: < 80 fL

  • normocytic: 80-100 fL

  • macrocytic: > 100 fL

MCH: mean corpuscular hemoglobin

- Hgb per RBC (pg); normal 27-33 pg

  • hypochromic: < 26 pg (pale)

  • normochromic: 26-33 pg

  • hyperchromic: > 33 pg (dark)

MCHC: mean corpuscular hemoglobin concentration

- Hgb concentration (g/dL); normal 32-36 g/dL

  • hypochromic: < 32 g/dL (decreased Hgb conc.)

  • normochromic: 32-36 g/dL

  • hyperchromic: > 36 g/dL (increased, rare)

RDW: red cell distribution width

- variation in RBC size (%); normal < 15%

  • > 15% = anisocytosis (increased variation in size)


5
New cards

Labs for Anemia

Iron Studies: iron deficiency anemia

  • serum iron (amount of iron in blood) —→ decreased

  • ferritin (iron stores) —> decreased

  • total iron-binding capacity (TIBC) (ability to bind iron) —> increased

Reticulocyte Count: shows bone marrow response

- Normal range: 0.5-1.5% of RBCs

Interpretation:

  • increased reticulocyte count:

    • blood loss

    • hemolysis (active bone marrow)

  • decreased reticulocyte count:

    • bone marrow suppression

    • decreased RBC production

Vitamin B12 & Folate Labs:

- both B12 and folate deficiencies cause macrocytic anemia

  • B12 deficiency:

    • decreased vitamin B12

    • increased methylmalonic acid (MMA)

    • increased homocysteine

  • Folate deficiency:

    • decreased folate

    • increased homocysteine (only)


6
New cards

Iron Deficiency Anemia (IDA)

- microcytic, hypochromic

Causes & Risk Factors:

  • inadequate iron intake, decreased absorption, or increased iron loss —> decreased iron available for Hgb synthesis —> decreased RBC production

- Common causes

  • chronic blood loss (ex. GI bleeding)

  • heavy menstrual bleeding (menstruation)

  • malabsorption (ex. celiac disease, gastric bypass)

  • increased demand (pregnancy, growth)

S/S:

  • fatigue, weakness, decreased exercise tolerance

  • pallor (mucous membranes, conjunctiva, nail beds)

  • dyspnea (with exertion)

  • headache

  • brittle nails (koilonychia)

  • hair loss

  • glossitis (smooth, red tongue)

  • pica (ex. ice, nonfood items)

Diagnostic Findings:

- CBC:

  • decreased Hgb/Hct

  • decreased MCV

  • decreased MCH

  • increased RDW (increased variation in RBC size)

- Peripheral smear:

  • microcytic, hypochromic RBCs with anisocytosis and poikilocytosis (pencil cells may be seen)

- Iron studies:

  • decreased serum iron

  • dcreased ferritin (low iron stores)

  • increased TIBC

- Other:

  • reticulocyte usually normal or low (decreased production)

Treatment:

- Oral iron supplements (first-line)

  • Ex, ferrous sulfate, ferrous gluconate, ferrous fumarate

  • take with vitamin C to enhance absorption

  • common side effects: GI upset, constipation, dark stools

- IV iron therapy —> use if unable to tolerate oral iron, malabsorption, or need for rapid repletion (ex. severe deficiency, pregnancy, chronic kidney disease)

- Treat underlying cause:

  • address source of blood loss

  • manage conditions causing malabsorption

  • provide dietary eduction


7
New cards

Ferrous sulfate

Class: iron supplement

Use: treats iron deficiency anemia (IDA)

MOA: replaces iron —> supports hemoglobin synthesis and RBC production

Dose: adult PO: 325 mg (about 65 mg elemental iron), 1-3x day

ADR: constipation, dark stools, dyspepsia, rash; liquid may stain teeth; anaphylaxis more with IV administration

Interactions: antacids, PPIs, calcium, tetracyclines —> decreased iron absorption

Contraindications/Cautions: hemochromatosis; uses caution with PUD or UC

Nursing: monitor Hgb/Hct and response; give with vitamin C to increase absorption

Key point: separate from calcium/antacids and interacting medications; consider stool softener PRN

8
New cards

Vitamin B12 Deficiency Anemia

Cause:

  • decreased intake (vegan diet)

  • decreased absorption (gastric surgery, malabsorption)

Key Effects:

  • decreased DNA synthesis —> macrocytic anemia

  • neurologic involvement (paresthesia, imbalance, memory changes)

Clinical Features:

  • fatigue, pallor

  • macrocytic anemia

  • neurologic symptoms: paresthesia, imbalance, memory changes

Diagnostic Findings:

  • increased MCV

  • macro-ovalocytes

  • hypersegmented neutrophils

  • decreased B12

  • increased methylmanoic acid (MMA)

Treatment: cyanocobalamin (oral or IM)

9
New cards

Pernicious Anemia

Cause:

  • autoimmune loss of intrinsic factor

  • impaired B12 absorption

Key Effects:

  • decreased DNA synthesis —> macrocytic anemia

  • neurologic involvement (same as B12 deficiency)

  • lifelong replacement needed

Clinical Features:

  • fatigue, pallor

  • macrocytic anemia

  • neurologic symptoms: paresthesia, imbalance, memory changes

Diagnostic Findings:

  • increased MCV

  • macro-ovalocytes

  • hypersegmented neutrophils

  • positive intrinsic factor antibodies

  • decreased B12

  • increased methylmalonic acid (MMA)

Treatment: lifelong B12 replacement (oral or IM)

10
New cards

Folate (B9) Deficiency

Cause:

  • decreased intake (poor diet, alcoholism)

  • increased demand (pregnancy)

Key Effects:

  • decreased DNA synthesis —> macrocytic anemia

  • no neurologic symptoms

  • increased risk of fetal neural tube defects

Clinical Features:

  • fatigue, pallor

  • macrocytic anemia

  • no neurologic symptoms

  • increased risk of fetal neural tube defects (pregnancy)

Diagnostic Findings:

  • increased MCV

  • macro-ovslocytes

  • hypersegmented neutrophils

  • decreased folate

  • methylmalonic acid (MMA) usually normal

Treatment: oral folic acid; correct underlying cause

11
New cards

Cyanocobalamin (Vitamin B12)

Class: vitamin supplement

Use: treats B12 deficiency and pernicious anemia

MOA: replaces B12 —> restores DNA synthesis and RBC production, division, and maturation

ADR: headache, nausea, diarrhea, possible hypokalemia during rapid correction

Interactions: omeprazole may decrease B12 absorption; chloramphenicol may decrease hematologic response

Nursing: assess CBC, reticulocytes and neurologic symptoms; oral or IM based on need

Daily Requirement: adults —> 2.4 mcg, pregnancy 2.6 mcg, lactation 2.8 mcg

Key point: pernicious anemia requires lifelong B12 replacement; monitor neurologic recovery

12
New cards

Folic acid (Vitamin B9)

Class: water-soluble vitamin

Use: treats folate-deficiency anemia

MOA: supports DNA synthesis —> normal RBC production

ADR: generally well tolerated; warmth or flushing with IV administration

Interactions: methotrexate and phenytoin can affect folate levels or treatment

Nursing: give before contraception and during pregnancy; assess cause of deficiency

Daily requirement: adults —> 400 mcg, pregnancy —> 600 mcg, lactation —> 500 mcg

Key point: folate helps prevent neural tube defects; exclude B12 deficiency before folate-only treatment

13
New cards

Anemia of Chronic Disease (AOCD)

Mechanism: chronic inflammation leads to decreased RBC production, decreased iron availability, and shortened RBC lifespan

- Chronic inflammation —> cytokines (ex. IL-6, TNF-alpha)

  • increased hepcidin

  • directly suppresses erythropoietin (EPO) production

- Decreased iron availability

  • increased hepcidin reduces intestinal iron absorption and traps iron in macrophages

- Decreased erythropoietin (EPO) response

  • inflammatory cytokines suppress renal erythropoietin (EPO) production

- Decreased RBC production

  • inadequate bone marrow response

- Decreased RBC lifespan

  • RBC lifespan shortened from 100-120 days to 60-90 days

Causes:

  • chronic infection (HIV, TB)

  • chronic immune activation (RA, SLE)

  • malignancy (Hodgkin’s lymphoma, lung cancer, breast cancer)

  • chronic kidney disease (CKD) —> decreased erythropoietin production —> decreased RBC production

Treatment:

  • Control underlying disease/inflammation

    • treat infections (HIV, TB)

    • manage autoimmune disease (RA, SLE)

    • treat malignancy

    • optimize CKD management

  • Erythropoietin (EPO) therapy if CKD-related

    • consider erythropoietin (EPO) therapy in CKD-related anemia


14
New cards

Leukopenia & Neutropenia

Definitions:

  • Leukopenia

    • WBC < 4,000 μL

    • decrease in total white blood cells

  • Neutropenia

    • neutrophils < 1,500 μL (severe < 500 μL)

    • high risk for infection

Normal vs Neutropenia:

  • Normal: 1,500-8,000 μL (adequate infection defense)

  • Neutropenia: < 1,500 μL (fewer neutrophils —> increased infection risk)

    • severe: < 500 μL

Causes:

  • chemotherapy and radiation

  • bone marrow disorders or suppression

  • infections (viral, bacterial)

  • medications (ex. antineoplastics)

  • autoimmune disorders

  • nutritional deficiency (ex. vitamin deficiency)

  • chronic illness

S/S:

  • often asymptomatic

  • fatigue

  • fever and chills

  • recurrent infections

  • mouth ulcers

  • pneumonia

  • increased risk for serious infection

Diagnostics:

  • CBC with differential (decreased WBC and ANC)

  • blood cultures (if fever)

  • bone marrow biopsy (if indicated)

Treatment:

  • G-CSF (Filgrastim) —> increased WBC production

  • antibiotics —> prevent or treat infection

  • adjust causative medications

  • bone marrow transplant (if severe or refractory)

Neutropenic Fever: MEDICAL EMERGENCY

  • fever ≥ 100.4 °F in a neutropenic patient

    • report immediately

    • obtain blood cultures (as ordered)

    • start empiric broad-spectrum antibiotics (as ordered)

    • monitor vital signs and CBC (WBC, ANC)


15
New cards

Filgrastim (Neupogen)

Class: hematopoietic growth factor; granulocyte colony-stimulating grwoth factor (G-CSF)

MOA: stimulates bone marrow —> increased neutrophil production (ANC)

Uses: chemo-induced neutropenia; after stem cell transplant; selected severe neutropenias

ADR: bone pain; leukocytosis; rare but splenic rupture or ARDS

Contraindications: serious hypersensitivity

Interactions: avoid administration within 24 hours before or after cytotoxic chemotherapy

Similar Drugs: pegfligrastin (Neulasta) —> longer acting

Nursing: monitor CBC/ANC; follow prescribed hold parameters; assess bone pain

Safety: report fever, left upper abdominal/shoulder pain, or breathing difficulty promptly

Key point: ANC-based dose adjustments depend on indication and protocol — not one universal cutoff

16
New cards

Thrombocytopenia

Definition & Platelet Levels:

  • platelets < 150,000 μL

  • increased bleeding risk when < 50,000 μL

  • severe spontaneous bleeding when < 20,000 μL

Causes:

- decreased production (bone marrow failure)

  • aplastic anemia

  • leukemia

  • chemotherapy

  • radiation

- increased destruction

  • immune thrombocytopenic purpura (ITP) — autoimmune

  • infections (ex. HIV, HCV)

  • drugs (ex. heparin induced thrombocytopenia — HIT)

- increased consumption

  • disseminated intravascular coagulation (DIC)

  • thrombotic thrombocytopenic purpura (TTP)

S/S:

  • purpura

  • petechiae

  • prolonged bleeding

  • epistaxis

  • bleeding gums

  • hematuria

  • melena

Diagnostics:

  • CBC —> decreased platelets

  • peripheral smear

  • ± bone marrow biopsy (if indicated)

Management:

  • mild thrombocytopenia —> treat underlying cause

  • ITP: steroids/IVIG/ ± splenectomy/TPO agonists

  • marrow suppression (chemo): thrombopoietic CSF (romiplostim, oprelvekin)

  • severe ( < 10,000 or active bleeding): platelet transfusion

Nursing:

  • monitor platelet count and assess for bleeding

  • implement bleeding precautions

    • soft toothbrush

    • electric razor

    • avoid NSAIDs, IM injections, and invasive procedures

  • report any bleeding or bruising


17
New cards

Leukemia

Definition:

  • acute or chronic, uncontrolled proliferation of abnormal WBCs in bone marrow and blood

  • malignant disorder of hematopoietic (blood-forming) cells

  • M = myeloid —> granulocytes, RBC, platelets

  • L = lymphocytic —> lymphocytes (B & T cells)

Types:

  • Acute (AML, ALL):

    • rapid increase of immature blasts

    • medical emergency

  • Chronic (CML, CLL):

    • slow increase of more mature but dysfunctional WBCs

    • often asymptomatic early

Causes/Risk Factors:

  • genetic: Philadelphia chromosome (especially CML)

  • environmental: radiation, chemical exposure (ex. benzene)

Clinical Manifestations:

  • fatigue

  • fever

  • weight loss

  • increased infections (due to dysfunctional WBCs)

  • easy bruising/bleeding (decreased platelets)

  • bone pain

  • lymphadenopathy (enlarged lymph nodes)

Diagnostics:

  • increased WBC count on CBC (often with abnormal/dysfunctional cells)

  • peripheral smear (abnormal cells, blasts)

  • bone marrow biopsy (increased blasts)

  • genetic testing (ex Philadelphia chromosome in CML)

Treatment:

  • chemotherapy: decreased blasts

  • targeted therapy (TKIs): inhibits specific genetic abnormalities

  • stem-cell transplant: curative option for selected patients

  • supportive care: transfusions, infection prevention

Key point:

- Leukocytosis

  • reactive/adaptive increase in WBCs (ex. infection, inflammation, stress, certain medications)

  • WBCs usually mature and functional

- Leukemia

  • malignant proliferation of abnormal WBCs

  • WBCs often immature and dysfunctional (blasts)


18
New cards

Polycythemia Vera (PV)

Defintion:

  • chronic myeloproliferative neoplasm with a JAK2 mutation leading to persistent increase in RBC production

  • often associated with increased WBCs and platelets

Types of Erythrocytes:

- Primary

  • myeloproliferative neoplasm

  • JAK2 mutation (about 95%)

  • clonal overproduction of RBCs (often increase in WBCs and platelets)

  • low erythropoietin (EPO)

- Secondary

  • due to increased EPO from chronic hypoxia or other cuases (ex. lung/heart disease, high altitude, smoking, tumors)

  • JAK2 mutation absent

  • normal or increased EPO

Patho:

  • JAK2 mutation (constitutive activation)

  • uncontrolled RBC production (± increased WBCs and platelets)

  • increased blood viscosity

  • increased risk for thrombosis (arterial and venous)

Diagnostics:

  • CBC —> increased RBC count, Hgb, Hct (± WBCs/platelets)

  • JAK2 mutation testing

  • low serum erythropoietin (EPO)

  • bone marrow biopsy (hypercellular marrow with panmyelosis, if indicated)

S/S:

  • headache

  • dizziness

  • ruddy complexion (plethora)

  • aquagenic pruritus (itching after warm shower)

  • fatigue

  • erythromelalgia (burning, redness in hands/feet)

  • increased risk for thrombosis (DVT, PE, MI, stroke) or bleeding (especially with very high platelets)

Treatment:

  1. Phlebotomy

  • first-line treatment

  • goal: hematocrit < 45%

  1. low-dose aspirin (81-100 mg/day)

  • decreased thrombotic risk (if no contraindications)

  1. hydroxyurea

  • cytoreductive therapy

  • decreased RBC, WBC, and platelet production

  1. ropeginterferon alfa-2b (Besremi)

  • pegylated interferon (JAK2 pathway)

  • decreased JAK2-mutant stem cell activity

Key point:

- PV

  • JAK2 mutation (positive)

  • primary bone marrow disorder

  • increased RBC mass (± WBCs and platelets)

  • low EPO

- Secondary (reactive) Eryhthrocytosis

  • no JAK2 mutation

  • due to increased EPO (ex. chronic hypoxia, lung/heart disease, high altitude, smoking, tumors)


19
New cards

Essential Thrombocythemia (ET)

Defintion:

  • chronic myeloproliferative neoplasm with a JAK2 mutation leading to increased persistent platelet production

  • clonal overproduction of megakaryocytes in bone marrow

Types:

- Primary

  • myeloproliferative neoplasm

  • JAK2 mutation (50-60%)

  • clonal overproduction of megakaryocytes (increased platelets)

- Secondary

  • response to another condition (ex. inflammation, infection, iron deficiency, malignancy, or post-splenectomy)

  • JAK2 mutation absent

  • normal or increased other labs related to cause

Patho:

  • JAK2 mutation (constitutive activation)

  • increased megakaryocyte production in bone marrow

  • increased platelets

  • increased risk for thrombosis (arterial and venous) ± bleeding

Diagnostics:

  • CBC: increased platelets (> 450,00)/μL)

  • JAK2 mutation testing (for ET)

  • bone marrow biopsy (increased megakaryocytes, if indicated)

Clinical Manifestations:

  • often asymptomatic

  • headache, dizziness, visual changes

  • increased thrombosis risk (ex. stroke, MI, DVT)

  • ± easy bruising/bleeding (ex. gums, nose)

  • erythromelalgia (burning, redness in hands/feet)

Treatment:

  • antiplatelet agent (low-dose aspirin) —> decreased clot risk. (if no contraindications)

  • cytoreductive therapy (hydroxyurea or anagrelide) —> decreased platelet production

  • monitor for thrombosis and bleeding

Key point:

- ET:

  • primary bone marrow disorder (JAK2 mutation)

  • persistent increased platelets ( > 450,000 μL)

  • treat with aspirin ± hydroxyurea or anagrelide

- Reactive (secondary) Thrombocytosis

  • due to another condition (infection, inflammation, iron deficiency, malignancy, post-splenectomy)

  • JAK2 mutation absent

  • usually transient and treat underlying cause


20
New cards

Aplastic Anemia

Definition: bone marrow failure —> decreased production of all blood cells (pancytopenia) —> anemia + leukopenia + thrombocytopenia

Causes:

  • autoimmune destruction

  • radiation

  • toxins (ex. benzene)

  • drugs (ex. chloraphenicol)

S/S:

  • fatigue (decreased RBCs)

  • infections (decreased WBCs)

  • bleeding (decreased platelets)

Findings:

  • decreased RBCs, WBCs, platelets (pancytopenia)

  • normocytic, normochromic RBCs

  • decreased reticulocytes

  • bone marrow failure: hypocellular marrow replaced by fat (hallmark)

  • normal iron, B12, folate levels

Treatment:

  1. bone marrow stimulants

  • epoetin alfa, filgrastin

  1. immunosuppressive therapy

  • antithymocyte globulin (ATG) + cyclosporine

    • immune destruction —> marrow recovery

  1. bone marrow transplant

  • iff severe or refractory


21
New cards

Epoetin Alfa (Epogen)

Class: hematopoietic growth factor; erythropoietin

MOA: stimulates RBC production in bone marrow

Use: anemia due to CKD, chemotherapy, or HIV therapy

ADR: fever, headache, N/V/D, edema; hypertension

Black Box: increased risk of clots, stroke, MI, and death

Contraindications: uncontrolled HTN; avoid excessive Hgb rise

Interactions: dialysis patients may need more hepain

Similar drugs: darbepoetin alfa (Aranesp)

Nursing:

  • monitor BP, Hgb/Hct; assess for DVT, stroke, MI

  • DO NOT shake vial; use the lowest effective dose


22
New cards

Myelodysplatic Syndromes (MDS)

Overview: group of bone marrow disorders where stem cells fail to mature properly —> produce abnormal, ineffective blood cells

Patho:

  • defective maturation (dysplasia) of hematopoietic stem cells in the bone marrow

  • leads to production of abnormal, ineffective blood cells and increased apoptosis —> cytopenias

Result: decreased production of healthy RBCs, WBCs, and platelets —> pancytopenia

Clinical Manifestations:

  • anemia —> fatigue, pallor, dyspnea

  • neutropenia —> increased infection risk

  • thrombocytopenia —> bleeding, petechiae

  • often gradual onset and may be asymptomatic

Progression: damaged marrow may evolve to acute myeloid leukemia (AML)

Management:

  • Supportive care

    • transfusions

    • antibiotics

  • Stimulants

    • EPO

    • G-CSF

  • Drug therapy (chemotherapy)

    • azacitidine

    • decitabine

  • Curative option

    • bone marrow transplant


23
New cards

Thalassemia

Definition: genetic disorder

  • doesn’t make enough normal Hgb chains (alpha or beta) so the RBCs are fragile and break down early —> microcytic anemia

  • autosomal recessive inheritance (both parents must be carriers)

Types:

- Alpha

  • 1-4 gene deletions —> severity ranges from mild to fatal

  • more common in Southeast Asian, Chinese, and African ancestry

- Beta

  • decreased Beta-chain production —> trait minor, intermedia, or major

  • more common in Mediterranean, Middle Eastern, and Asian ancestry

Patho:

  • abnormal and/or not enough alpha or beta globin chains

  • imbalanced globin chains (excess unpaired chains)

  • ineffective erythropoiesis and increased RBC destruction (hemolysis)

  • microcytic and hypochromic anemia because not enough Hgb

S/S:

  • fatigue

  • pallor (conjuctiv, mucous membranes)

  • splenomegaly

  • dark urine (hemoglobinuria in severe hemolysis)

Diagnostic Findings:

- CBC:

  • decreased Hgb/Hct

  • decreased MCV (microcytic)

  • decreased MCH (hypochromic)

- Peripheral smear:

  • microcytic, hypochromic RBCs with target cells

- Iron studies:

  • usually normal (unlike iron deficiency anemia)

- Hemoglobin electrophoresis:

  • confirms diagnosis (especially Beta-thalassemia)

Treatment:

  • Blood transfusions

    • for moderate to severe anemia

    • corrects anemia and improves symptoms

  • Iron chelation therapy

    • prevents iron overload from repeated transfusions

    • ex. deferoxamine, deferasirox, deferiprone

  • Supportive care

    • folic acid, monitor for complications (ex. growth, bone changes)

Key point: abnormal and/or not enough alpha or beta globin changes —> fragile RBCs that break down early; microcytic and hypochromic anemia because not enough Hgb, not iron deficiency

24
New cards

Hemolytic Anemia

Definition: premature destruction of RBCs —> anemia

Causes:

  • autoimmune (ex. warm or cold antibodies)

  • hereditary (ex. G6PD deficiency, hereditary spherocytosis, thalassemia)

  • infections (ex. malaria)

  • drugs (ex. sulfa, dapsone)

G6PD deficiency (cause): decreased G6PD enzyme —> oxidative stress —> RBC destruction (especially with certain drugs, food, or infections)

Patho:

  • RBC membrane damage or enzyme deficiency

  • RBCs destroyed in circulation or spleen

  • increased bilirubin, LDH, and decreased haptoglobin

Diagnostics:

- CBC:

  • decreased Hgb, Hct (anemia), increased reticulocytes (if bone marrow is responding)

  • increased bilirubin (indirect), increased LDH

  • decreased haptoglobin

  • peripheral smear (ex. spherocytes, fragmented cells, target cells —> depending on cause)

S/S:

  • fatigue, weakness

  • jaundice (yellowing of skin/eyes)

  • dark urine

  • splenomegaly (especially with chronic hemolysis)

  • possible pain (ex. in malaria)

Treatment:

  • treat underlying cause (ex. remove trigger, treat infection)

  • folic acid supplementation (increased RBC production)

  • blood transfusions (if severe anemia)

  • corticosteroids or immunosuppressants (for autoimmune hemolysis)

  • avoid triggering drugs/foods (G6PD deficiency)

    • avoid oxidizing drugs (ex. sulfa, dapsone, antimalarials), flava beans, and infections

    • supportive care (ex. hydration, treat precipitating factors)


25
New cards

Sickle Cell Anemia

Definition & Patho:

  • genetic disorder —> abnormal hemoglobin (HbS)

  • sickle-shaped, rigid RBCs —> vaso-occlusion (obstructs blood flow and decreased O2 delivery to tissues)

  • inherited in an autosomal recessive pattern —> both parents must carry the gene

Diagnostics:

  • sickle-shaped RBCs on peripheral smear

  • hemoglobin electrophoersis —> shows HbS

  • decreased Hgb/Hct, increased reticulocytes (chronic hemolysis)

  • increased bilirubin (jaundice)

  • may see pigment gallstones on imaging

S/S:

  • pain crisis —> vaso-occlusion & tissue ischemia

  • fatigue —> anemia & decreased O2 delivery

  • jaundice —> increased RBC breakdown

  • delayed growth —> chronic hypoxia

  • organ damage —> spleen, kidneys, liver, heart

Complications:

  • acute chest syndrome —> pneumonia, lung infarcts

  • stroke —> blocked cerebral vessels

  • organ damage —> spleen, liver, kidneys (infarcts —> chronic kidney disease)

  • retinal infarcts —> blindness

  • avascular necrosis —> femoral ehad

  • iron overload —> heart, liver (due to repeated transfusions)

  • increased risk for infections —> asplenia (functional)

  • osteomyelitis —> bone infarction (fingers and toes)

Treatment & Crisis Care:

- Disease modifying treatment

  • hydroxyurea —> fetal hemoglobin (HbF) —> decreased sickling

  • blood transfusions —> prevent/treat selected complications

  • hematopoietic stem cell transplant —> potentially curative (selected patients)

  • avoid unnecessary iron supplementation —> give only if iron deficient

- Acute pain crisis (vaso-occlusion)

  • rapid pain management —> opioids for severe pain

  • hydration —> maintain euvolemia (avoid fluid overload)

  • O2 therapy —> hypoxemic

  • incentive spirometry —> prevent pulmonary complications

  • monitor —> SpO2, pain, fever, respiratory status

- Acute chest syndrome (EMERGENCY)

  • oxygen —> correct hypoxemia

  • antibiotics —> empiric coverage (including atypicals)

  • incentive spirometry

  • analgesia

  • blood transfusion (when indicated)

  • exchange transfusion —> severe or rapidly worsening cases


26
New cards

Hydroxyurea

Class: antineoplastic agent; antimetabolite

Use: sickle cell anemia; polcythemia vera; essential thrombocythemia, chronic myeloid leukemia (CML)

MOA: increased fetal hemoglobin (HbF) —> decreased sickling and pain crises AND inhibits enzyme that makes DNA —> decreased DNA synthesis and production of blood cells (RBC, WBC, platelets)

ADR: bone marrow suppression (decreased WBCs, platelets); N/V

Nursing: monitor CBC; hold for low counts per protocol; report fever/infetion

Safety: use gloves to handle capsules; avoid pregnancy

Teaching: take as prescribed; maintain hydration; keep lab appointments

Key point: prevents crises — it does not treat an acute crisis

27
New cards

Hemostasis

Definition: how the body stops bleeding

Steps:

  1. Vasoconstriction —> injured vessel narrows to reduce blood loss

  2. Platelet plug (primary hemostasis) —> platelets stick to the injury and build a temporary plug

  3. Coagulation (secondary hemostasis) —> a clotting fator cascade generates fibrin to strengthen and stabilize the plug

Coagulation:

  • Initiation (extrinsic pathway): injury exposes tissue factor (TF), which quickly starts the cascade

  • Amplification (intrinsic pathway): activates additional factors to make more Factor X and thrombin (strengthens the response)

  • Common pathway: Factor Xa + Factor Va convert prothrombin (Factor II) to thrombin (Factor IIa), which converts fibrinogen to fibrin

  • Clot stabilization: Factor XIIIa cross-links fibrin strands to make a strong, stable clot

Key points:

  • extrinsic pathway initiaties coagulation

  • intrinsic pathway amplifies the response

  • thrombin drives positive feedback

  • Factor XIIIa stabilizes the clot by cross-linking fibrin


28
New cards

Coagulation Disorders & Modifiers

Hypercoagulability:

  • increased clot formation

  • excessive coagulation or impaired natural anticoagulation

  • Ex.

    • Factor V Leiden

    • Antiphospholipid syndrome

    • DVT/PE

Bleeding disorders:

  • decreased effective clot formation

  • platelet abnormalities, clotting-factor deficiencies, or excessive fibrinolysis

  • Ex.

    • hemophilia

    • Von Willebrand disease

    • ITP

    • DIC

Coagulation modifiers:

  • medications alter clot formation or breakdown

  • may inhibit clotting, dissolve exisiting clots, or promote hemostasis

  • Ex.

    • antiplatelets

    • anticoagulants

    • thrombolytics

    • hemostatic agents


29
New cards

Coagulation & Hemostasis Tests

Coagulation pathways:

  • PT/INR —> extrinsic/common pathways; monitors warfarin

  • aPTT —> intrinsic/common pathways; monitors IV heparin

  • anti-Xa —> monitors selected heparin therapy

Platelets/Primary hemostasis:

  • platelet count —> identifies thrombocytopenia and bleeding risk

Other:

  • D-dimer —> fibrin breakdown; negative result helps rule out DVT/PE in low-risk patients

  • liver function tests —> liver produces most clotting factors

Key point: elevated D-dimer is non specific; it does NOT confirm DVT/PE

30
New cards

Inherited (Genetic) Hyper-coagulable Disorders

Factor V Leiden:

  • mutation in factor V —> resistance to activated Protein C (decreased inactivation of factor V)

  • increased risk for DVT/PE

Prothrombin gene mutation (G20210A):

  • increased prothrombin production

  • increased clot formation

Protein C/S deficiency:

  • decreased natural anticoagulation (less inhibition of clotting)

  • increased thrombosis risk

Antithrombin deficiency:

  • decreased inhibition of thrombin and Factor Xa

  • increased thrombosis risk


31
New cards

Acquired Hypercoagulable Disorders & Risk Factors

Antiphospholipid Syndrome (APS):

  • autoantibodies (lupus anticoagulant, anticardiolipin) that promote clot formation

  • venous/arterial thrombosis and recurrent pregnancy loss

Malignancy: increased procoagulant activity from cancer cells

Pregnancy, Postpartum, and Estrogen Exposure: increased clotting factors

Immobility: venous stasis (slower blood flow)

Surgery/Trauma: tissue injury + immobility —> increased clotting risk

32
New cards

Hyper-coagulability Clinical Manifestations & Managment

Patho:

  • hyper-coagulability —> increased thrombin —> increased fibrin —> increased pathologic clot formation

  • vascular obstruction —> decreased perfusion —> ischemia or infarction

Clinical manifestations:

  • DVT —> unilateral leg swelling, pain, warmth, redness

  • PE —> sudden dyspnea, chest pain, tachycardia

  • Other complications —> stroke, MI, tissue ischemia

Management & prevention:

  • anticoagulants —> heparin, LMWH, warfarin, DOACs

  • prevention —> early ambulation, sequential compression devices (SCDs), hydration, smoking cessation

  • nursing priorities —> monitor for thrombosis, bleeding, and treatment complications


33
New cards

Antithrombotic Therapy

Purpose: prevent or treat harmful blood clot formation (DVT, PE, stroke, ACS)

Mechanism: reduce platelet aggregation, inhibit clotting factors, or dissolve fibrin clots

Major drug classes & examples:

  • Antiplatelets —> aspirin (decreased TXA2); clopidogrel (blocks P2Y12); eptifibatide (GP IIb/IIIa)

  • Anticoagulants —> heparin/LMWH (increase antithrombin); warfarin (decrease vitamin K factors); DOACs (inhibit IIa or Xa)

  • Thrombolytics —> alteplase, tenectap;ase (activate plasmin to break down fibrin

Major risk: bleeding, including intracranial hemorrhage with thrombolytics

Key point:

  • anticoagulants prevent clot growth

  • thrombolytics dissolve existing clots


34
New cards

Aspirin (Acetylsalicylic Acid)

Class: antiplatelet; COX-1 inhibitor

MOA: irreversibly inhibits COX-1 —> decreased Thromboxane A2 —> decreased platelets activation and aggregation

Route: PO

Major ADR: bleeding, GI irritation/ulcers

Safety: avoid with active bleeding; Reye’s syndrome risk in children with viral illness

35
New cards

Clopidogrel (Plavix)

Class: antiplatelets; P2Y12 (ADP) receptor inhibitor

Similar Drugs: prasugrel (Effient), ticagrelor (Brilinta)

MOA: blocks P2Y12 receptors —> decreased platelet activation and aggregation

Route: PO

Major ADR: bleeding/hemorrhage

Black Box: reduced effectiveness in CYP2C19 poor metabolizers

Nursing:

  • monitor: bleeding, bruising, black/tarry stools

  • interactions: NSAIDs/anticoagulants —> increased bleeding risk

  • teaching: do not stop prescribed therapy without provider instructions

Key point: antiplatelets prevent platelet aggregation —> help prevent arterial clots

36
New cards

Eptifibatide

Class: antiplatelet; GP IIb/IIIa inhibitor

MOA: blocks GP IIb/IIIa receptors —> prevents fibrinogen binding —> decreased platelet aggregation

Route: IV

Use: ACS and other selected coronary interventions

Major ADRs: severe bleeding, thrombocytopenia

Nursing:

  • monitor: bleeding, platelet count, hemoglobin/hematocrit

  • assess: IV/access sites —> bleeding or hematoma

  • renal function: decreased kidney function —> may require dose adjustment

  • interactions: anticoagulants/other antiplatelets —> increased bleeding risk

  • safety: avoid unnecessary invasive procedures; report significant bleeding

Key point: GP IIb/IIIa inhibitors block the final common step of platelet aggregation

37
New cards

Heparin

Class: anticoagulant

MOA: inhibits Factor Xa and thrombin (IIa)

Route: IV or SC —> rapid anticoagulation

Major ADR: bleeding, heparin-induced thrombocytopenia (HIT)

Monitoring: aPTT or anti-Xa, platelets

Antidote: protamine sulfate

Key point: monitor bleeding, avoid IM injections

  • aPTT/anti-Xa monitoring


38
New cards

Low-molecular weight heparin (LMWH)

Class: anticoagulant

Prototype: Enoxaparin

MOA: mainly inhibits Factor Xa

Route: SC —> rotate injection sites; do not rub

Major ADR: bleeding; HIT less common

Monitoring: no routine aPTT; monitor platelets and renal function

Reversal: protamine sulfate —> partial reversal

Nursing:

  • monitor bleeding; avoid IM injections

  • Black Box: spinal/epidural bleeding —> possible paralysis

Key point: no routine aPTT monitoring


39
New cards

Heparin-induced Thrombocytopenia (HIT)

Definition: serious immune reaction to heparin —> increased platelet activation —> increased blood clots (thrombosis)

Patho: antibodies form against heparin-PF4 complexes —> platelets become activated and consumed —> decreased platelet count

Key finding: ≥ 50% drop in platelets from baseline —> usually occurs 5-10 days after starting heparin

S/S: new DVT/PE, limb pain/ischemia or skin necrosis —> indicates possible thrombosis

Nursing:

  • monitor: platelet trends —> ≥ 50% decrease or new thrombosis —> suspect HIT

  • take action: suspected HIT —> STOP all heparin (including flushes) —> notify provider immediately

  • treatment: stop heparin —> and astart alternative non-heparin anticoagulant (ex. argatroban, bivaliriudin — IV direct thrombin inhibitors)

  • safety: avoid LMWH and routine platelet transfusions in acute HIT

Key point: HIT = decreased platelets but increased risk of blood clots — NOT primary bleeding

40
New cards

Warfarin (Coumadin)

Class: anticoagulant; vitamin K antagonist

MOA: blocks vitamin K recylcing —> decreased production of clotting factors II, VII, IX, X

Route: PO —> delayed anticoagulant effect

Major ADR: bleeding/hemorrhage

Black Box: major or fatal bleeding

Contraindications: active major bleeding; generally avoided in pregnancy

Interactions: many medications and changes in vitamin K intake affect INR

Nursing:

  • monitor: PT/INR —> usually 2-3; some mechanical valves require higher targets

  • diet: maintain consistent vitamin K intake (leafy greens)

  • antidote: vitamin K (phytonadione)

  • severe bleeding: 4-factor prothrombin complex concentrate (PCC) + IV vitamin K

  • teaching: regular INR checks; report bleeding

Key point:

  • INR monitoring + vitamin K reversal

  • used for mechanical heart valves; DOACs are not


41
New cards

Apixaban (Eliquis)

Class: direct oral anticoagulant (DOAC)

MOA: blocks factor Xa —> decreased thrombin formation

Route: PO —> usually twice daily

Major ADR: bleeding/hemorrhage

Reversal: 4-factor PCC may be used for severe bleeding per protocol

Nursing:

  • monitoring: no routine INR or aPTT; assess bleeding, CBC, kidney function

  • interactions: NSAIDs/aspirin —> increased bleeding risk

  • black box: stopping early —> increased thrombosis; spinal/epidural bleeding risk

  • teaching: do NOT stop abruptly; take consistently


42
New cards

Dabigatran (Pradaxa)

Class: direct oral anticoagulant (DOAC)

MOA: blocks thrombin (IIa) —> decreased fibrin formation

Route: PO —> usually twice daily

Major ADR: bleeding/hemorrhage

Reversal: idarucizumab (Praxbind) —> specific antidote)

Nursing:

  • monitoring: no routine INR or aPTT; assess bleeding, CBC, kidney function

  • interactions: NSAIDs/aspirin —> increased bleeding risk

  • black box: stopping early —> increased thrombosis; spinal/epidural bleeding risk

  • teaching: do NOT stop abruptly; take consistently


43
New cards

Nursing considerations anticoagulants

  • Assess for bleeding: bruising, bleeding gums, hematuria, black/tarry stools

  • Monitor for thrombosis: leg swelling/pain, sudden dyspnea, chest pain

  • Avoid NSAIDs/aspirin unless prescribed: increased bleeding risk

  • Bleeding precautions: soft toothbrush, electric razor, prevent falls/injury

  • Before procedures: notify provider; anticoagulants may need to be held as ordered

  • Patient education: take exactly as prescribed; never skip, double, or stop doses without instructions

  • Report immediately: uncontrolled bleeding or symptoms of DVT/PE

Key point: anticoagulants prevent clot formation but increase bleeding risk


44
New cards

Alteplase (Activase)

Class: thrombolytics (fibrinolytics)

Similar drugs: tenecteplase (TNKase)

MOA: converts plasminogen —> plasmin —> breaks down fibrin —> dissolves existing clots

Route: IV; may be delivered delivered to a clot during selected procedures

Use: select patients with acute ischemic stroke, PE, or MI

Major ADR: severe bleeding, especially intracranial hemorrhage

Contraindications: active bleeding, intracranial hemorrhage, or other major bleeding risks

Nursing:

  • before administration: screen for contraindications; verify treatment eligibility and timing

  • monitor: neurological status, vital signs, bleeding

  • safety: avoid unnecessary injections/invasive procedures

  • report immediately: severe headache, sudden neurological changes, or bleeding

Key point: anticoagulants prevent clot growth; thrombolytics dissolve existing clots

45
New cards

Bleeding Disorders

Platelet adhesion disorders:

  • Von Willebrand Disease (VWD) —> inherited deficiency or dysfunction of von Willebrand factor; impaired platelet adhesion

Clotting factor deficiencies:

  • hemophilia A —> Factor VIII deficiency

  • hemophilia B —> Factor IX deficiency

Platelet destruction disorders:

  • immune thrombocytopenia (ITP) —> acquired autoimmune destruction of platelets

Consumptive coagulopathies:

  • disseminated intravascular coagulation (DIC) —> widespread clotting consumes platelets and clotting factors, results in bleeding


46
New cards

Von Willebrand Disease (VWD)

Defintion: most common inherited bleeding disorder —> deficiency or dysfunction of vWF (platelet adhesion defect)

- vWF Types:

  • Type 1: decreased vWF quantity (mild, most common)

  • Type 2: decreased vWF function

  • Type 3: nearly absent vWF (severe, rare)

Testing: decreased vWF antigen/activity, ± decreased Factor VII

S/S: easy bruising, nosebleeds, heavy menses, increased bleeding after surgery, dental work, or injury

Treatment: depends on type and severity

  • Desmopressin (DDAVP) —> increased vWF release (most cases)

  • vWF/Factor VIII concentrate for severe cases

  • antifibrinolytics (ex. TXA)


47
New cards

Hemophilia A & B

Definition:

  • X-linked bleeding disorders affecting the intrinsic pathway

  • Hemophilia A: factor VIII deficiency

  • Hemophilia B: factor IX deficiency

Testing:

  • increased aPTT (normal PT and platelets)

  • Factor VIII or IX assay —> differentiates A vs B

S/S:

  • prolonged bleeding, easy bruising

  • hemarthrosis —> joint pain and swelling

  • excessive bleeding after injury or surgery

Treatment:

  • factor VIII replacement —> Hemophilia A

  • factor IX replacement —> Hemophilia B

  • DDAVP —> mild Hemophilia A

  • antifibrinolytics (TXA) —> stabilize clots

  • avoid NSAIDs and trauma


48
New cards

Disseminated intravascular coagulation (DIC)

Definition: secondary process —> widespread activation of clotting —> microthrombi + factor consumption —> bleeding

Testing: increased PT/aPTT, increased D-dimer, decreased platelets, decreased fibrinogen, fragmented RBCs (schistocytes) by mechanical damage

S/S: bleeding (bruising, oozing), thrombosis, organ ischemia

Treatment:

  • treat underlying cause (sepsis, trauma, obstetric)

  • supportive: fresh frozen plasma, platelets, cryoprecipitate if bleeding

  • heparin of predominately thrombotic

Key point: causes both clotting and bleeding because microthrombi consume platelets and clotting; treat the underlying cause first

49
New cards

Immune Thrombocytopenic Purpura (ITP)

Definition: autoimmune platelet destruction —> isolated thrombocytopenia (< 100,000 platelets)

Testing: CBC = low platelets, normal WBC/RBC; peripheral smear normal morphology

S/S: petechiae, purpura, mucosal bleeding, nosebleeds, gum bleeding

Treatment:

  • corticosteroids (first line)

  • IVIG or Rho(D) immune globulin if severe

  • splenectomy for refractory cases

  • avoid NSAIDs/aspirin


50
New cards

Hemostatic Therapy

Purpose: prevent or control excessive bleeding caused by impaired clot formation or excessive clot breakdown

Mechanism: promote hemostasis through two major actions

  1. increased clotting factor availability —> improved clot formation

  2. decreased fibrinolysis —> stabilization of existing clots

Examples:

  • Desmopressin (DDAVP) —> increased release of vWF and factor VIII —> improves clot formation

  • Tranexamic acid (TXA) —> blocks plasminogen binding to fibrin —> prevents clot breakdown

  • Aminocaproic acid (Amicar) —> blocks plasminogen activation —> prevents clot breakdown

Major risks: thromboembolic complications in susceptible patients

Key point:

  • DDAVP promotes clot formation

  • antifibrinolytics prevent clot breakdown


51
New cards

Desmopressin (DDAVP)

Class: synthetic ADH analog —> hemostatic analog

MOA: stimulates V2 receptors —> increased release of vWF and Factor VIII —> increased clot formation

Route: IV, SC, intranasal (formulation dependent)

Use: selected patients with mild Hemophilia A or von Willebrand disease (primarily type 1)

Major ADR: hyponatremia, water intoxication, headache, flushing

Contraindications: hyponatremia, significant renal impairment, certain cardiac conditions

Nursing:

  • monitor: serum sodium, fluid balance, urine ouptut

  • fluid restriction: limit free water —> prevent water intoxication

  • assess: headache, confusion, weight gain —> possible hyponatremia

  • safety: monitor response to therapy; repeated doses may have decreased effect over time (tachyphylaxis)

Key point:

  • DDAVP increases vWF and factor VIII

  • antifibrinolytics prevent fibrin breakdown


52
New cards

Tranexamic acid (TXA)

MOA: blocks plasminogen binding to fibrin —> decreased fibrin breakdown

Route: PO, IV, topical (often off-label)

Uses: trauma, surgery, postpartum hemorrhage, heavy menses, epistaxis

Major ADR: seizures (high doses), hypotension (rapid IV), thrombotic complications

Nursing:

  • monitor: bleeding control and signs of DVT/PE

  • administration: give IV slowly —> rapid administration may cause hypotension

  • renal function: assess kidney function —> may require dose adjustment

  • safety: avoid with active intravascular clotting; assess thrombotic risk


53
New cards

Aminocaproic Acid (Amicar)

MOA: inhibits plasminogen activation —> decreased plasmin —> decreased fibrin breakdown

Route: PO/IV

Uses: surgical bleeding, excessive fibrinolysis, hemophilia-related bleeding

Major ADR: hypotension (rapid IV), myopathy, thrombotic complications

Nursing:

  • monitor: bleeding control and signs of DVT/PE

  • administration: give IV slowly —> rapid administration may cause hypotension

  • renal function: assess kidney function —> may require dose adjustment

  • safety: avoid with active intravascular clotting; assess thrombotic risk


54
New cards

Other conditions that impair coagulation

Liver disease:

  • Effect on coagulation: decreased clotting factors and decreased natural anticoagulants (ex. protein C/S, antithrombin)

  • Bleeding/Clotting risk: increased bleeding and thrombosis risk

  • Treatment: treat underlying disease process; blood products or vitamin K when indicated

Hypothermia & metabolic acidosis:

  • Effect on coagulation: decreased clotting factor activity and platelet function

  • Bleeding/Clotting risk: increased bleeding risk

  • Treatment: rewarming and correction of acidosis

Vitamin K:

  • Effect on coagulation: decreased functional factors II, VII, IX, X

  • Bleeding/Clotting risk: increased bleeding risk

  • Treatment: vitamin K (phytonadione)

Hypocalcemia:

  • Effect on coagulation: required cofactor (factor IV) for coagulation reactions

  • Bleeding/Clotting risk: increased bleeding risk (especially if severe)

  • Treatment: calcium replacement (when indicated)


55
New cards

Shock

Definition: inadequate tissue perfusion —> decreased oxygen delivery —> anaerobi metabolism —> increased lactic acid —> metabolic acidosis —> cell injury —> organ dysfunction

Goal of Compensation: maintain perfusion via neurohumoral activation (SNS, RAAS, ADH)

Failure of Compensation: progressive ischemia —> multi-organ failure —> death

Imbalance:

  • increased oxygen demand —> increased metabolic demand

  • decreased oxygen supply

    • insufficient oxygen supply

    • inadequate tissue perfusion

    • cellular hypoxia

Progression: decreased O2 delivery —> anaerobic metabolism —> increased lactic acid and metabolic acidosis —> cell injury —> organ dysfunction


56
New cards

Common pathophysiology of shock

  1. Initiating mechanism

  • decreased circulating volume, decreased cardiac output, or decreased vascular tone —> tissue hypoperfusion

  1. Cellular dysfunction

  • decreased O2 delivery —> anaerobic metabolism —> increased lactate & metabolic acidosis —> decreased ATP production

  1. Vicious cycle

  • decreased ATP —> cellular injury —> inflammation & endothelial dysfunction —> worsening hypoperfusion —> organ dysfunction


57
New cards

Stages of shock

Initial: decreased CO and O2 delivery —> early anaerobic metabolism

Compensatory: SNS + RAAS + ADH activation —> increased HR, increased RR, vasoconstriction, decreased urine output

Progressive: compensatory failure —> hypotension —> organ hypoperfusion

Irreversible: multi-organ failure —> ischemia —> death

58
New cards

Signs of shock

Early signs:

  • MAP decreased 10 mmHg from baseline

  • effective compensation

  • increased O2 —> vital organs

  • increased heart rate

Compensatory signs (non-progressive):

  • MAP decreased 10-15 mmHg from baseline

  • increased renin-angiotensin-aldosterone (RAAS)/ADH

  • vasoconstriction

  • increased pulse pressure

  • increased HR

  • decreased pH

  • restless

  • apprehensive

Progressive (intermediate):

  • MAP decreased 20 mmHg from baseline

  • tissue/organ hypoxia

  • decreased urine (oliguria)

  • weak, rapid pulse

  • decreased pH

  • sensory/neurologic changes

Refractory signs (irreversible):

  • excessive cell/organ damage

  • multi-system organ failure

  • decreased pH


59
New cards

Vascular response

Trigger: baroreceptors in the carotid sinuses & aortic arch detect drop in BP

Mechanism: decreased stretch —> SNS activation …

  • arteriolar vasoconstriction —> increased SVR —> supports increased BP

  • venoconstriction —> increased venous return —> increased preload & CO

  • blood redistribution —> prioritizes heart and brain perfusion

Result: maintains BP and vital organ perfusion during early shock

Prolonged shock:

  • sustained vasoconstriction —> decreased skin, renal, GI perfusion

  • endothelial injury + systemic inflammation —> coagulation activation —> microthrombi and clotting consumption —> DIC


60
New cards

Chemoreceptor response

Trigger: peripheral chemoreceptors (carotid & aortic bodies) detect decreased O2, increased CO2, or decreased pH

Mechanism: stimulates medulla —> SNS activation

  • increased HR and contractility —> increased CO

  • vasoconstriction —> maintain BP and oxygen delivery

  • increased respiratory rate —> blow off CO2 —> correct acidosis

Timeline: rapid (seconds) —> maintains short-term oxygenation

Limitation: if hypoxia persists —> lactic acidosis —> chemoreceptor fatigue

61
New cards

Renal response

Trigger: decreased renal perfusion —> juxtaglomerular cells release renin (10-60 min)

Cascade:

  • renin —> angiotensin I —> angiotensin II —> potent vasoconstriction —> increased BP

  • angiotensin II —> stimulates aldosterone —> sodium and water retention —> increased intravascular volume

Early indicator: decreased urine output = renal hypoperfusion

Late effect: persistent ischemia —> acute tubular necrosis (ATN) —> renal failure

62
New cards

Adrenal response

SNS —> Adrenal medulla —> Epi/NE: increased HR, contractility, and vasoconstriction —> increased BP and CO —> rapid perfusion support

HPA Axis —> Adrenal cortex —> Cortisol: increased catecholamine sensitivity & glucose availability —> sustained vascular and metabolic support

Clinical significance:

  • short-term: maintains BP & tissue perfusion:

  • prolonged stress: hyperglycemia & immunosuppression —> increased complications


63
New cards

Cerebral response

Goal: maintain constant cerebral blood flow despite systemic hypotension

Mechanism: autoregulation dilates cerebral arterioles when MAP decreases or CO2 increases

Critical threshold:

  • CPP (60-100) = Map (70-100) - ICP (5-15)

  • ischemia occurs if CPP < 60 mmHg

Progression: prolonged hypotension —> loss of autoregulation —> cerebral hypoxia, edema, decreased LOC, coma

64
New cards

Hepatic response

Epinephrine: stimulates glycogenolysis —> glucose release for energy

Vasoconstriction: shunts flow to vital organs —> risk of hepatic ischemia

Metabolic Role: impaired lactate clearance & detoxification —> increased toxins, ammonia, lactic acidosis —> to multi-organ failure (MODS)

65
New cards

Pulmonary response

Acidosis —> tachypnea: compensatory hyperventilation (Kussmaul-type) to decrease CO2

Result: temporary pH correction and improved alveolar O2 exchange

Progression: endothelial injury —> increased capillary permeability —> pulmonary edema —> decreased gas exchange —> ARDS

66
New cards

Classification of shock

Obstructive:

  • compression/obstruction

  • cardiac tamponade

  • tension pneumothorax

Cardiogenic:

  • pump failure

  • blunt cardiac injury

  • dysrhythmia

  • myocardial infarcation

Hypovolemic:

  • reservoir depletion

  • hemorrhage

  • hypovolemia

Distributive:

  • vasodilation

  • anaphylaxis

  • sepsis

  • spinal cord injury (neurogenic shock)

Key point: all lead to inadequate tissue perfusion


67
New cards

Hypovolemic shock

Mechanism: decreased intravascular volume —> decreased venous return (preload) —> decreased CO —> decreased tissue perfusion

Compensatory: increased HR, vasoconstriction, fluid shift —> fail with severe loss

Types:

  • hemorrhagic: trauma, GI bleed, aneurysm rupture, post-surgical bleed

  • non-hemorrhagic: dehydration, burns, vomiting, diarrhea, diuresis, third-spacing (peritonitis, burns)

S/S:

- Early:

  • tachycardia, hypotension, narrow pulse pressure (decreased stroke volume)

  • cool, clammy, pale skin (peripheral vasoconstriction —> increased SVR)

  • oliguria < 0.5 mL/kg/hr (decreased renal perfusion)

  • anxiety, restlessness (decreased cerebral perfusion)

  • hemodynamics: decreased preload (CVP), decreased CO from decreased venous return, increased SVR compensatory response

- Advanced:

  • hypotension unresponsive to fluids; weak, thready pulses

  • hypothermia (impaired thermoregulation from poor perfusion)

  • confusion —> lethargy —> coma (cerebral hypoxia)

  • hemodynamics: persistently decreased CO despite fluid resuscitation, decreased mixed venous O2 saturation (increased extraction), narrow or collapsing pulse pressure

Diagnostics:

- Laboratory findings:

  • decreased Hgb/Hct: after fluid shift; may be normal early

  • increased lactate: marker of tissue hypoperfusion

  • increased BUN/Cr (> 20:1): prerenal azotemia from hypoperfusion

  • increased Na+/osmolarity: especially with dehydration

  • metabolic acidosis: from anaerobic metabolism (lactic acid)

  • coagulopathy: increased PT/INR, decreased platelets in hemorrhagic shock or with MTP

- Imaging & additional evaluation:

  • FAST(focused assessment with sonography in trauma): detect intra-abdominal bleeding

  • CT or angiography: localize internal hemorrhage

  • CXR/PXR: identify fractures or bleeding sources

  • continuous hemodynamic and urine output monitoring: assess response to resuscitation

Treatment:

  • Fluid resuscitation:

    • start with crystalloids (NS or LR) —> rapid infusion

    • if hemorrhagic —> activate massive transfusion protocol (1:1:1 PRBC: FFP: platelets)

  • Hemostatic measures:

    • identify and control bleeding source (surgical, mechanical, or interventional)

    • apply direct pressure or hemostatic dressings

    • consider early tranexamic acid (TXA) to stabilize clot formation

  • Monitor: mental status, MAP ≥ 65 mmHg, urine output, lactate

  • Vasopressors: norepinepherine —> only after adequate volume restoration

  • Correct underlying cause: control bleeding, treat dehydration, burns, etc.

Key point:

  • tachycardia, narrow pulse pressure, and cool, clammy skin may precede hypotension and can be a compensatory response

  • a normal blood pressure does not exclude significant hypovolemia

  • progressive loss of intravascular volume —> compensatory vasoconstriction (increased DVR) —> decreased venous return and CO —> tissue hypoperfusion (renal, cerebral, systemic)


68
New cards

Cardiogenic shock

Definition: pump failure leading to decreased CO, resulting in inadequate tissue perfusion

Patho: decreased cardiac contractility (pump failure) —> decreased cardiac output —> increased LV filling pressures —> pulmonary congestion & hypoxia —> decreased systemic perfusion (multi-organ hypoperfusion)

Cycle: decreased CO —> decreased coronary perfusion —> increased myocardial ischemia —> further decreased contractility. —> cycle repeats (vicious cycle)

Common causes:

  • myocardial infarction (MI) (most common)

  • cardiomyopathy (ex. dilated, hypertrophic)

  • arrhythmias (ex. VT, high-grade heart block)

  • valvular disease (ex. mitral regurgitation, aortic stenosis)

Hemodynamic findings:

  • decreased cardiac output (CO) and cardiac index (CI)

  • increased filling pressures: increased PCWP (≥ 18 mmHg) and increased CVP

  • increased systemic vascular resistance (SVR)(compensatory)

Clinical presentations:

  • chest pain (commonly from MI)

  • dyspnea, orthopnea, crackles/rales (pulmonary congestion)

  • cyanosis, cool, clammy skin (decreased perfusion)

  • decreased urine output (< 0.5 mL/kg/hr)

  • JVD + hepatic congestion (if right ventricular failure)

  • weak or thready pulses, hypotension, tachycardia

  • altered mental status, anxiety, restlessness (decreased cerebral perfusion)

Diagnostics/Findings:

  • EKG: ST elevation or arrythmia (ex. VT, AFib, HB)

  • Echocardiogram: decreased LVEF, wall motion abnormalities, decreased stroke volume

  • Labs: increased troponin, increased BNP, increased lactate (tissue hypoperfusion)

  • CXR: pulmonary congestion or edema; possible cardiomegaly

Treatment:

  • Inotropes: dobutamine or milrinone —> increased contractility and CO

  • Vasopressors: norephineprine —> maintain MAP ≥ 65 mmHg

  • Diuretics: furosemide —> decreased pulmonary congestion

  • Revascularization: PCI or CABG for MI-related shock

  • Mechanical support: IABP or LVAD for refractory cases

  • Avoid fluid overload: worsense pulmonary edema


69
New cards

Obstructive shock

Definition: mechanicla blockage to cardiac filling or output, leading to decreased CO and tissue perfusion

Patho: mechanical obstruction (to filling or output) —> decreased venous return (preload) —> decreased cardiac output (CO) —> decreased tissue perfusion (shock)

Common causes:

  • pulmonary embolism (increased RV afterload)

  • tension pneumothorax (mediastinal shift —> decreased venous return)

  • cardiac tamponade (increased pericardial pressure —> decreased filling)

  • aortic dissection (compromised major arterial flow)

Hemodynamics: decreased CO, decreased preload, increased RAP/CVP, increased SVR (compensatory)

Clinical presentations:

  • sudden, severe hypotension with tachycardia and weak, thready pulses (decreased preload and CO)

  • dyspnea, tachypnea, cyanosis (impaired oxygenation)

  • distended neck veins/JVD (increased right atrial pressure, venous congestion)

  • cool, clammy skin (SNS vasoconstriction

  • restlessness, anxiety, altered LOC (early cerebral hypoperfusion)

  • pulsus paradoxus (exaggerated > 10 mmHg drop in systolic BP during inspiration; notably in tamponade)

Specific presentations:

  • cardiac tamponade

    • muffled heart sounds

    • narrow pulse pressure

    • increased JVD, clear lungs

  • tension pneumothorax

    • absent breath sounds (affected side)

    • tracheal deviation

    • sudden hypoxia

  • pulmonary embolism

    • pleuritc chest pain

    • tachypnea, hypoxia

    • ± hemoptysis

  • aortic dissection

    • sudden “tearing” chest or back pain

    • pulse deficits

    • differential BP between arms

Diagnostics:

  • EKG: right strain, electrical alternans

  • Echo: RV dilation, pericardial effusion

  • CTA: PE or aortic dissection

  • CXR: pneumothorax

Treatment:

  • PE: tPA or catheter thrombolysis —> heparin LMWH

  • Tension pneumothorax: immediate needle decompression —> chest tube

  • Tamponade: pericardiocentesis —> surgical window if recurrent

  • Dissection: urgent surgery + BP control (B-blocker)


70
New cards

Distributive shock

Definition: systemic vasodilation causing relative circulatory insufficiency and tissue hypoperfusion

Patho: widespread vasodilation (decreased SVR) —> blood pooling (capacitance) —> decreased venous return (preload) —> decreased cardiac output (CO)

Subtypes: septic, anaphylactic, neurogenic

Hemodynamics: increased CO (normal or high), decreased SVR, decreased preload

Clinical Presentation:

  • warm skin initially (vasodilation)

  • cool skin as hypoperfusion progresses

Key point: pathologic, widespread vasodilaltion causing decreased SVR, blood pooling, and decreased CO

71
New cards

Septic shock

Patho: infection —> cytokine storm (IL-1, IL-6, TNF-alpha) —> endothelial damage —> increased nitric oxide —> massive vasodilation

Clinical presentation:

- Hyperdynamic (warm) phenotype

  • normal increased CO, decreased SVR

  • warm, flushed skin; bounding pulses

  • widened pulse pressure (vasodilation)

- Hypodynamic (cold) phenotype

  • decreased CO (often), impaired tissue perfusion

  • cool, mottled skin; weak pulses

  • narrow pulse pressure may occur

Diagnostic findings:

- Laboratory

  • lactate (≥ 2 mmol/L) —> tissue hypoperfusion (≥ 4 mmol/L = higher risk)

  • WBC —> leukocytosis or leukopenia (late)

  • procalcitonin —> supports bacterial infection

  • blood cultures (positive) —> identify organism (often gram-negative)

  • CRP/ESR —> systemic inflammation

  • metabolic acidosis (decreased pH, HCO3-) —> tissue hypoxia

  • organ injury labs (increased BUN/Cr, increased LFTs, increased bilirubin, increased troponin)

- Imaging/Evaluation

  • CXR/CT/Ultrasound —> identify infection source (ex. pneumonia, abscess)

  • Echocardiography —> assess cardiac function if hypotension persists

Treatment:

  • antibiotics —> broad spectrum within 1 hour and then tailor to cultures

  • fluids —> 30 mL/kg crystalloid (NS/LR)

  • vasopressors —> norepinephrine (1st line), add vasopressin if needed

  • source control —> drain abscess; remove infected catheters or devices

  • monitoring (goals) —> MAP ≥ 65 mmHg; lactate clearance (≥ 10-20% decrease in 2-6 hours)

  • adjuncts —> hydrocortisone if refractory to pressors; O2 support; nutrition

Key point:

  • produces variable hemodynamic patterns

  • patients may present with a warm, hyperdynamic or cold, hypodynamic phenotype —> progression between these states is not inevitable

  • Dx: identify infection and assess severity (lactate, cultures, organ injury, imaging)

  • Tx: early antibiotics, fluids, vasopressors, source control, and goal directed monitoring


72
New cards

Anaphylactic shock

Patho:

  • allergen (food, drug, insect sting) —> IgE mediated mast cell-basophil degranulation —> release of histamine, tryptase, leukotrienes, prostaglandins —> vasodilation (decreased SVR), increased capillary permeability (decreased preload), bronchoconstriction, edema

Clinical presentation:

  • rapid onset (minutes) after exposure

  • skin: urticaria, flushing, pruritus, angioedema

  • respiratory: wheezing, stridor, dyspnea

  • cardiovascular: hypotension, tachycardia, syncope

  • GI: nausea, vomiting, cramping, diarrhea

  • hemodynamics: decreased SVR, decreased preload, decreased CO (may occur)

Diagnosis:

  • mostly clinical: rapid onset of typical symptoms (ex. airway, respiratory, cardiovascular, skin, or GI) after allergen exposure (ex. food, drug, insect sting)

Treatment:

  • Epinephrine (first-line): 0.3-0.5 mg IM in the mid-anteriolateral thigh; repeat q5-15 min

  • airway & O2: O2 and airway support (ex. impending airway edema)

  • fluids: rapid isotonic crystalloid (ex. 1-2 L)

  • adjuncts: H1 antihistamine (ex. diphenhydramine), H2 blocker (famotidine), and corticosteroid (methylprednisolone)

  • observation: ≥ 4-6h (longer if severe or biphasic risk)

Key point:

  • life-threatening allergic reaction with rapid onset

  • Epinephrine IM is the first-line, immediate treatment

  • treat airway, breathing, and circulation, and monitor for recurrence (biphasic reaction)


73
New cards

Neurogenic shock

Definition: distributive shock from loss of sympathetic tone, commonly after spinal cord injury (SCI)

Patho: loss of sympathetic tone (ex. SCI ≥ T6) —> unopposed vagal activity (increased parasympathetic) —> systemic vasodilation (decreased SVR) —> decreased venous return (decreased preload) —> decreased CO and BP with bradycardia (hallmark)

Causes:

  • spinal cord injury: cervical or upper thoracic (T1-T6)

  • head trauma: brainstem injury affecting autonomic control

  • spinal anesthesia: rare sympathetic blockade

  • CNS insult: tumors, lesions, or demyelinating disease

Clinical presentation:

- Early:

  • decreased BP with bradycardia (hallmark)

  • warm, dry, flushed skin below injury (loss of vasomotor tone)

  • flaccid paralysis, decreased reflexes, anhidrosis below lesion

  • normal or decreased JVD (no venous congestion)

  • hypothermia from vasodilation & impaired thermoregulation

- Progressive

  • dizziness, syncope, decreased LOC (decreased cerebral perfusion)

  • decreased urine output (renal hypoperfusion)

  • respiratory compromise if injury above C5 (decreased diaphragmatic function)

  • decreased sweating below lesion (impaired temperature control)

Diagnostic findings:

- Clinical assessment:

  • vital signs —> hypotension + bradycardia (± hypothermia)

  • neurologic exam —> deficits consistent with high spinal cord injury (≥ T6)

  • history/mechanism —> trauma or other spinal cord injury (ex. spinal anesthesia

- Imaging/Evaluation:

  • MRI/CT spine: confirm level and extent of spinal cord injury

  • Other studies: rule out other causes of shock (ex. hemorrhagic, septic, cardiogenic)

Treatment:

  • IV fluids: cautious volume replacement (ex. 500-1000 mL crystalloid) to optimize preload)

  • maintain BP: target MAP ≥ 85 mmHg to ensure spinal cord perfusion; avoid fluid overload

  • vasopressors: norephinephrine (preferred) or phenylephrine ro restore vascular tone

  • atropine: for symptomatic bradycardia

  • spinal stabilization/decompression: surgical or mechanical management as indicated

  • respiratory support: if high cervical injury (ex. ≥ C5), provide ventialotry support

  • prevent secondary injury: maintain oxygenation, normothermia, and adequate perfusion

Key point: NOT spinal shock

  • results from loss of sympathetic tone with vasodilation and bradycardia, whereas spinal shock is a transient loss of all neurologic function after SCI


74
New cards

MODS (multiple organ dysfunction syndrome)

Patho: persistent hypoperfusion + systemic inflammation —> dysfunction of ≥ 2 organ systems

Key clinical findings:

  • oliguria (decreased urine output)

  • altered LOC

  • respiratory failure

  • hepatic dysfunction (increased liver enzymes)


75
New cards

ARDS (acute respiratory distress syndrome)

Patho: inflammatory alveolar-capillary injury —> pulmonary edema + impaired gas exchange

Key clinical findings:

  • severe hypoxemia (decreased spO2)

  • dyspnea/increased work of breathing

  • bilateral pulmonary opacities (ex. on CXR)


76
New cards

Virchow’s Tirad

Venous stasis: slowed blood flow —> immobility, bed rest, prolonged travel

Endothelial injury: vessel wall damage —> surgery, trauma, catheters

Hypercoagulability: increased tendency to clot —> inherited thrombophilia, cancer, pregnancy

Key point: explains the major mechanisms contributing to venous thrombosis

77
New cards

Venous thrombosis (& Virchow’s triad)

Definition: abnormal thrombus formation —> partial or complete obstruction of blood flow

Thrombus formation:

  • platelets + fibrin + RBCs —> clot formation

  • clot obstructs circulation —> impaired blood flow

Virchow’s triad:

  • Venous stasis: slowed blood flow —> immobility, bed rest, prolonged travel

  • Endothelial injury: vessel wall damage —> surgery, trauma, catheters

  • Hypercoagulability: increased tendency to clot —> inherited thrombophilia, cancer, pregnancy

Key point: explains the major mechanisms contributing to venous thrombosis


78
New cards

Thrombus vs. Embolus

Thrombus:

  • blood clot that forms and remains within a blood vessel

  • may partially or completely obstruct blood flow

Embolus:

  • clot or other material that travels through circulation

  • lodges in another vessel —> impaired perfusion

Venous thromboembolism (VTE):

  • Deep vein thrombosis (DVT): thrombus forms in a deep vein, usually in the leg

  • Pulmonary embolism (PE): embolus travels to and obstructs a pulmonary artery

Key point: a DVT can dislodge —> travel to the lungs —> cause a potentially life-threatening arterial blockage in the pulmonary arteries called a PE

79
New cards

DVT (deep vein thrombosis)

Definition: thrombus formation in a deep vein, most commonly in the lower extremities

Patho:

  • Virchow’s triad —> promotes venous thrombus formation

  • thrombus obstructs venous flow —> increased venous pressure

  • impaired venous return —> swelling, pain, and inflammation

  • thrombus may dislodge —> pulmonary embolism

Complications:

  • PE: embolism to pulmonary circulation

  • post-thrombotic syndrome: venous valve damage —> chronic edema, pain, skin changes or ulcers

Virchow’s triad:

  • venous stasis: slowed blood flow (ex. immobility, bed rest)

  • endothelial injury: vessel wall damage (ex. surgery, trauma)

  • hypercoagulability: tendency to clot (ex. cancer, pregnancy)

Risk factors:

  • immobility: bed rest, hospitalization, prolonged travel

  • surgery or trauma: especially orthopedic procedures

  • hypercoagulable conditions: cancer, pregnancy, estrogen therapy, inherited thrombophilia

  • other risks: previous DVT/PE, obesity

Clinical manifestations:

  • unilateral pain swelling

  • pain or tenderness, commonly in the calf

  • warmth, erythema, or discoloration

  • may be asymptomatic

Nursing priorities:

  • assess and compare both extremities

  • do not massage the affected leg

  • notify provider —> anticipate diagnostic ultrasound

Clinical Probability:

  • Wells score: estimates likelihood of DVT based on symptoms and risk factors

  • guides laboratory testing and imaging

Laboratory testing:

  • D-dimer: measures fibrin degradation products

    • negative D-dimer: helps exclude DVT in appropriately selected low-risk patients

    • elevated D-dimer: nonspecific —. does not confirm DVT

Diagnostic imaging:

  • Venous duplex ultrasound: first-line diagnostic test

    • thrombus —> vein does not compress normally

  • computed tomography (CT) or magnetic resonance (MR) venography: selected cases when ultrasound is inconclusive or pelvic DVT is suspected

Key point:

  • impairs venous return and may cause life-threatening PE

  • new unilateral swelling + pain + warmth —> suspect DVT

  • D-dimer helps rule out DVT in selected patients; duplex ultrasound confirms the diagnosis



80
New cards

DVT management

Pharmacologic management:

  • anticoagulants: first line for most confirmed DVTs —> prevent clot extension + new clot formation

  • DOACs: apixaban, rivaroxaban —> preferred for many eligible patients

  • UFH/LMWH: alternatives —> based on clinical circumstances

  • warfarin: used in selected patients —> requires INR monitoring

  • duration: ≥ 3 months —> longer if recurrent DVT or high bleeding risk

Nonpharmcologic management:

  • early ambulation: once anticoagulated + clinically stable

  • limb care: avoid massaging the affected extremity

  • limb-threatening DVT: urgent vascular evaluation —> possible catheter-directed treatment for clot removal

Monitoring & safety:

  • bleeding: brusing, hematuria, GI bleeding, severe headache

  • UFH: monitor aPTT or anti-Xa (as ordered)

  • HIT: monitor platelet counts (when indicated)

  • PE warning signs: sudden dyspnea, chest pain, tachycardia, immediate evaluation

Prevention Strategies:

- Enhance mobility:

  • early ambulation: get patients moving as soon as it is safe

  • regular mobility: leg exercises (ex. ankle pumps) and frequent walks

- Use prophylaxis:

  • mechanical: sequential compression devices (SCDs) or compression stockings (when indicated)

  • pharmacologic: anticoagulants (ex. low dose UFH or LMWH) for eligible at-risk patients

Key point:

  • anticoagulants prevent blood clot progression; bleeding and signs of PE are major nursing priorities

  • early mobility, leg exercises, and apporpriate mechanical or pharmacological prophylaxis prevent the first DVT


81
New cards

Pulmonary Embolism (PE)

Definition: embolus, usually from a DVT, obstructs pulmonary arterial blood flow

  • can also arise from fat, air, amniotic fluid

Effects on Oxygenation:

  • obstructed pulmonary blood flow —> ventilation-perfusion mismatch (V/Q mismatch)

  • impaired gas exchange —> possible hypoxemia

Patho:

  • pulmonary artery obstruction —> increased pulmonary vascular resistance

  • increased resistance —> increased right ventricular (RV) afterload

  • RV dilation and dysfunction —> decreased left ventricular filling

  • decreased cardiac output —> hypotension and obstructive shock

Complications:

  • acute RV failure

  • obstructive shock and cardiac arrest

  • chronic thromboembolic pulmonary hypertension (CTEPH) —> persistent dyspnea

Common manifestations:

  • sudden dyspnea and tachycardia

  • pleuritic chest pain —> worsens with inspiration

  • tachycardia and possible hypoxemia

  • possible hemoptysis, anxiety, or syncope

High-risk findings:

  • hypotension —> decreased cardiac output

  • altered mental status —> impaired cerebral perfusion

  • cool skin, poor perfusion, or syncope

  • severe PE —> obstructive shock or cardiac arrest

Nursing priorities:

  • assess airway, breathing, circulation (ABCs)

  • monitor SpO2, BP, HR, and mental status

  • recognize hemodynamic deterioration —> activate emergency response

Clinical probability:

  • Wells score: estimates likelihood of PE

  • clinical probability and hemodynamic stability guide testing

Laboratory testing:

  • D-dimer: helps exclude PE in appropriately selected low-intermediate-risk patients

    • elevated D-dimer: nonspecific —> does not confirm PE

  • troponin/natriuretic peptides: may indicate RV strain and assist risk assessment

Diagnostic imaging:

  • CT pulmonary angiography (CTPA): primary confirmatory imaging test for most eligible patients

  • Ventilation/perfusion (V/Q) scan: alternative when CTPA is unsuitable

  • Echocardiography: evaluates RV dysfunction, especially in unstable patients

Additional assessment:

  • EKG: may show sinus tachycardia

  • ABGs: may show hypoxemia or respiratory alkalosis

  • neither EKG nor ABGs alone can confirm or exclude PE

Key point:

  • pulmonary obstruction —> RV strain —> decreased cardiac output —> potentially fatal obstructive shock

  • sudden dyspnea + chest pain + hypotension —> suspect life-threatening PE

  • clinical probability guides testing; CTPA is the primary confirmatory test for most eligible patients


82
New cards

PE management

Anticoagulation:

  • anticoagulation —> first-line for most patients; prevents recurrence

  • oral therapy —> DOACs preferred when eligible

  • injectible therapy —> LMWH over UFH when parenteral treatment is needed

  • warfarin —> preferred in thrombotic antiphospholipid syndrome

Thrombolytic therapy:

  • alteplase —> promotes clot breakdown

  • consider for high-risk PE with hemodynamic instability and acceptable bleeding risk

  • avoid routine thrombolysis in stable PE

Monitoring & safety:

  • watch for major bleeding (GI or intracranial)

  • review contraindications, renal function, and drug interactions

  • monitor BP, oxygenation, mental status, and response

  • initial treatment —> 3-6 months: reassess need for extension

Oxygenation & supportive care:

  • assess ABGs and monitor respiratory status —> maintain oxygenation

  • give supplemental oxygen for hypoxemia (SpO2 < 90%)

  • manage hypotension and impaired perfusion —> vasopressors (if needed)

  • escalate for worsening respiratory distress

Antithrombotic adjunct: inferior vena cava (IVC) filter

  • consider when VTE is present and anticoagulation is contraindicated

  • traps emboli to prevent new PE

  • does not dissolve existing clot

  • remove when appropriate —> typically within 3 months (or sooner if possible)

Advanced interventions (for select patients:

  • catheter-directed therapy (CDT): catheter delivery of a thrombolytic (ex. altepase) ± mechanical clot removal into pulmonary arteries

  • surgical embolectomy: urgent clot removal when indicated

Prevention strategies:

  • early mobility

    • ambulate early and regularly

    • reduce venous stasisand VTE risk, including PE

  • mechanical prophylaxis

    • use sequential compression devices (SCDs) when appropriate

    • promote venous return and reduce stasis

  • pharmacologic prophylaxis

    • give risk-based anticoagulation during hospitalization (ex. LMWH or UFH)

    • prevent VTE (DVT and PE) in at-risk patients

Key points:

  • anticoagulants —> prevent recurrent VTE; do not actually dissolve existing clot

  • thrombolytics —> actively dissolve clots in selected unstable patients

  • use early mobility, SCDs, and risk based anticoagulation to prevent a first PE (primary prevention)


83
New cards

Ischemic stroke

Definition: cerebral artery obstruction —> decreased cerebral blood flow —> neuronal injury and infarction

Etiology:

  • atherosclerotic (large-artery): plaque formation or rupture —> thrombosis or embolization

  • cardioembolic: clot forms in the heart )ex. atrial fibrillation) —> travels to cerebral circulation

  • small vessel (lacunar): occlusion of small penetrating cerebral arteries

  • often associated with chronic hypertension or diabetes

Underlying mechanism:

  • arterial obstruction —> decreased oxygen and glucose delivery

  • prolonged ischemia —> irreversible brain injury

Patho:

- Cerebral ischemia:

  • arterial occlusion —> decreased oxygen and glucose

  • decreased adenosine triphosphate (ATP) production —> failure of cellular ion pumps

  • cellular sodium and water accumulation —> cytotoxic edema

  • prolonged ischemia —> neuronal injury and infarction

- Infarct core vs. penumbra:

  • infarct core: irreversibly injured brain tissue

  • ischemic penumbra: hypoperfused tissue that may still be salvageable

  • without reperfusion —> penumbra may progress to infarction

- Treatment implication:

  • rapid reperfusion may restore blood flow and preserve threatened tissue

  • delayed treatment —> greater risk of permanent neurological deficits

Risk factors:

- Modifiable:

  • hypertension —> major risk factor

  • diabetes mellitus, dyslipidemia

  • smoking, obesity, physical inactivity

  • atrial fibrillation —> increased risk of cardioembolic stroke

- Nonmodifiable

  • increasing age

  • family history

  • prior transient ischemic attack (TIA) or stroke

  • sex-related differences in risk and outcomes

Clinical manifestations:

  • sudden unilateral weakness or numbness

  • facial droop, arm weakness

  • aphasia: difficulty speaking or understanding language

  • visual loss, dizziness, ataxia, or impaired balance

Stroke recognition: BE - FAST

  • Balance: difficulty

  • Eyes: sudden vision loss (usually one eye)

  • Facial: facial droop

  • Arm: arm weakness

  • Speech: speech difficulty

  • Time: call 911 immediately

Diagnostics:

  • immediate assessment

    • identify last-known-well time

    • assess ABCs, vital signs, and blood glucose

    • use NIHSS to quantify neurologic deficits and monitor changes

  • brain imaging

    • non-contrast CT of brain ≤ 20 minutes from arrival(urgent; excludes intracranial hemorrhage)

    • MRI: ≤ 60 minutes from arrival (more sensitive for early ischemic stroke)

  • vascular imaging

    • CT angiography (CTA): ≤ 30 minutes from arrival (detects large-vessel occlusion)

    • CT/MR perfusion: ≤ 60 minutes from arrival (helps identify potentially salvageable tissue in selected patients)

  • additional evaluation:

    • EKG: obtain early (detects atrial fibrillation or arrhythmias)

    • Ehocardiography: within 24hrs (evaluates possible cardiac embolic sources)

    • Labs: glucose, CBC, and coagulation studies: PT, INR, aPTT (± fibrinogen and platelet count)

Key point:

  • ischemic strokes have different causes, which influence acute treatment and secondary prevention

  • time is brain —> early reperfusion may save the ischemic penumbra

  • sudden focal neurological deficits —> active stroke response immediately

  • last known-well time + urgent brain imaging guide reperfusion eligibility


84
New cards

Ischemic stroke management

Pharmacologic:

  • initial assessment

    • CT or MRI: no intracranial hemorrhage

    • NIHSS: assess baseline stroke severity and neurological deficits

    • review anticoagulant use

    • check blood glucose and bleeding risk

    • ensure BP < 185/110 mmHg

  • IV thrombolytics

    • alteplase or tenecteplase —> fibrinolytics

    • treat eligible disabling stroke ≤ 4.5 hours (last known well time)

    • selected extended/unknown-onset —> imaging based eligibility

  • Post-thrombolysis management:

    • BP < 180/105 mmHg for 24 hrs

    • monitor for intracranial hemorrhage (ICH)

    • frequent neurologic and BP checks (first 24 hrs)

    • hold anticoagulants/antiplatelets for 24 hrs until follow up CT/MRI

  • Start secondary prevention

    • aspirin (ACA): start early after CT excludes bleeding (generally within 48 hrs); if thrombolytic given, wait 24 hrs and repeat CT/MRI first

    • anticoagulation: selected cardiembolic indications

    • statins: reduce future vascular risk

Nonpharmacologic:

  • mechanical thrombectomy (EVT)

    • endovascular removal of a clot from an occluded artery

    • for selected large-vessel occlusions

    • can be performed up to 24 hours after last known well-time (in selected patients)

  • early rehabilitation (when medically stable):

    • begin multidisciplinary rehabilitation assessment early once clinically stable

    • include physical, occupational, and speech-language therapy as directed

  • supportive care:

    • airway & oxygenation: maintain adequate oxygenatin (SpO2 ≥ 94%); treat hypoxia

    • blood pressure: avoid hypotension; follow reperfusion-specific BP targets (ex. after thrombolysis or thrombectomy)

    • temperature: treat fever (≥ 100.4 °F) and investigate the cause

    • glucose: correct hypoglycemia; manage persistent hyperglycemia (ex. 140-180 mg/dL) while avoiding overly intesive control

    • hydration: maintain euvolemia (adequate fluid volume); avoid dehydration

    • aspiration prevention: perform a swallow screen before oral intake

Primary prevention:

  • control medical risks:

    • hypertension —> treat: BP goal < 130/80 mmHg for most treated adults

    • diabetes: optimize glucose; manage weight

    • high cholesterol: statin when indicated by cardiovascular risk

    • atrial fibrillation: assess stroke risk; anticoagulate when indicated

  • healthy daily habits:

    • mediterranean-style diet; limit sodium

    • exercise ≥ 150 min/week moderate intensity; reduce prolonged sitting

    • stop smoking: avoid tobacco

    • maintain healthy weight and sleep

  • screen & individualize:

    • regular BP, glucose, lipid, and AF/risk assessment

    • address barriers to preventative care

    • aspirin in NOT routinely recommended solely to prevent a first stroke

Key point:

  • EVT restores blood flow in selected large-vessel occlusions, and supportive care plus early rehabilitation reduce secondary complications

  • start aspirin early once imaging excludes intracranial hemorrhgae; after thrombolysis, withhold for 24h and obtain follow-up CT/MRI

  • restore blood flow (reperfusion) when indicated and provide supportive care to prevent secondary brain injury

  • prevent a FIRST stroke: control BP and other vascular risks + sustain healthy habits


85
New cards

Ischemic stroke: cerebral edema & increased ICP

Development of cerebral edema:

  • ischemia —> cellular injury —> cytotoxic edema

  • later blood-brain barrier disruption —> vasogenic edema

  • severe swelling —> increased intracranial pressure (ICP)

Effects on cerebral perfusion:

  • increased ICP —> decreased cerebral perfusion

  • severe edema —> possible brain herniation

  • large cerebellar infarcts —> possible hydrocephalus and brainstem compression

Warning signs:

  • declining level of consciousness (LOC)

  • new or worsening neurological deficits

  • headache, vomiting, pupillary changes

  • Cushing’s triad —> late sign of increased ICP (hypertension, bradycardia, irregular respirations)

Management of cerebral edema:

  • urgent neurological reassessment and brain imaging

  • general measures: head of bed 30°, maintain oxygenation (SpO2 ≥ 94%), euvolemia, and normothermia

  • osmotherapy: hypertonic saline (ex. 3% NaCl) or mannitol to reduce ICP

  • decompressive surgery: for selected patients with life-threatening swelling

Key point:

  • sudden neurological deterioration may indicate cerebral edema or hemorrhage —> immediate escalation


86
New cards

Brain anatomy

Brain overview:

  • Cerebrum:

    • cognition, memory

    • voluntary motor/sensory integration

  • Cerebellum:

    • coordinates tone & balance via feeback loops

    • lesion —> ataxia

  • Brainstem

    • autonomic control (HR/BP/respiration)

    • reticular activation

  • Perfusion dependent:

    • high O2 and glucose need

    • rapid dysfunction with ischemia

Protective structures:

  • Scalp & skull: outer mechanical protection

  • Meninges: three layers (dura mater, araachnoid matter, pia matter) provide mechanical and barrier protection

  • CSF: buoyancy, waste clearance, and ICP stability (via the choroid plexus)

  • BBB: tight junctions between astrocytes; limits entry of toxins and pathogens

  • Disruption: plasma leak —> vasogenic edema —> increased ICP


87
New cards

Cerebral blood supply & CSF circulation

Main pathways to the brain:

  • anterior circulation (ICAs): right and left internal carotid arteries

  • posterior circulation (vertebrals —> basilar): right and left vertebral arteries join to fomr the basilar artery

  • Circle of Willis (collateral flow)

Blood supply: 2 internal carotid arteries (anterior) and 2 vertebral arteries (join to form the basilar artery; posterior) supply the brain and connect via the Circle of Willis

CSF flow (simplified):

  • produced by the choroid plexus (in ventricles)

  • ventricles (lateral —> third —> fourth)

  • subarachnoid space (around brain & spinal cord)

  • reabsorbed by arachnoid granulations (into venous sinuses)

CSF: produced by the choroid plexus in the ventricles, circulates through the ventricles to the subarachnoid space, and is reabsorbed by arachnoid granulation into venous sinuses

88
New cards

Cerebral blood flow & neurovascular regulation

Cerebral blood flow (CBF):

  • normal CBF: 50-60 mL/100g/min

  • neurons require a continuous supply of oxygen and glucose (aerobic metabolism)

Neurovascular unit: neurons, astrocytes, and endothelium work together (neurovascular unit) to match local blood flow to brain activity (increased activity —> increased CBF)

Autoregulation:

  • adjusts cerebral blood vessel diamter to keep CBF relatively constant despite changes in MAP (60-150 mHg)

  • may be impaired after brain injury (ex. TBI), making CBF more dependent on MAP

CO2 regulation:

  • increased CO2 (hypercapnia): vasodilation —> increased CBF and increased ICP

  • decreased CO2 (hypocapnia): vasoconstriction —> decreased CBF and increased risk of ischemia

Key point: CBF is regulated by the neurovascular unit, autoregulation, and CO2 levels; after TBI, autoregulation may be impaired, and abnormal CO2 levels can compromise cerebral perfusion and worsen secondary brain injury

89
New cards

Intracranial pressure (ICP) & Monro-Kellie Principle

Monro-Kellie Principle: the skull is a fixed volume containing: brain tissue + blood + CSF

Intracranial volume: small changes in one component must be balanced by changes in the others

  • Brain: 80%

  • CSF: 10%

  • Blood: 10%

ICP values:

  • normal: 5-15 mmHg

  • > 20 mmHg: concerning (increased risk of brain injury)

  • > 40 mmHg: high risk of herniation

Compensation sequence (increased volume):

  • increased CSF displacement (to spinal space)

  • decreased venous blood volume (venous outflow)

  • compensatory reserve exhausted

  • increased ICP and risk of herniation

Key point: the intracranial space is fixed, so an increase in the volume of brain tissue, blood, or CSF raises ICP

90
New cards

Cerebral perfusion pressure (CPP)

CPP = MAP - ICP

  • normal CCP (non-TBI): approximately 60-100 mmHg

  • severe TBI target: 60-70 mmHg; individualized

  • ICP > 22 mmHg: treat sustained elevations

Avoid hypotension and hypoxemia:

  • prevent secondary brain injury

Avoid aggressively raising CPP > 70 mmHg:

  • with fluids/vasopressors due to respiratory complications

Impaired autoregulation:

  • CBF becomes more pressure dependent

  • CPP targets may require individualization

Key point: in severe TBI, maintain adequate CPP while controlling ICP to preserve cerebral blood flow and prevent secondary brain injury

91
New cards

Cerebral edema

Vasogenic edema:

  • disruption of the blood brain barrier (BBB)

  • fluid leaks into the extracellular space

  • caused by trauma and inflammation

Cytotoxic edema:

  • cellular energy failure disrupts sodium-potassium pumps

  • Na+ and H2O accumulate inside brain cells

  • associated with hypoxia and ischemia

Key point: both types cause brain swelling —> increased ICP —> decreased cerebral perfusion —> secondary brain injury

92
New cards

Pathophysiology of increased ICP

Causes: trauma, hemorrhage, edema, tumor, infection, hydrocephalus

Compensation fails: increased intracranial volume —> increased ICP

Vicious cycle: increased ICP —> decreased CPP —> ischemia —> edema —> increased ICP

Consequences: herniation, coma, death

93
New cards

Signs of ICP

Early signs:

  • decreased LOC: restlessness, confusion, agitation

  • pupils: sluggish or unequal (anisocoria)

  • headache, nausea, projectile vomiting

Late sings:

  • fixed, dilated pupils

  • Cushing’s triad

    • increased BP (widened pulse pressure)

    • decreased HR

    • irregular respirations

  • posturing

    • decorticate (flexor)

    • decerebrate (extensor)

  • coma — brain death


94
New cards

Brain herniations

Definition: displacement of brain tissue across rigid barriers due to increased ICP

Key assessment clues:

  • decreased level of consciousness

  • pupillary changes (size or reactivity)

  • worsening neurologic signs (ex. new weakness, abnormal posturing)

Uncal (lateral transtentorial):

  • medial temporal lobe (uncus) shift inward and downward through the tentorial notch

  • hallmark: ipsilateral dilated nonreactive pupil (CN III)

  • may progress to brainstem compression

Central (downward transtentorial):

  • downward displacement of the diencephalon and midbrain through the tentorial notch

  • Hallmark: progressive bilateral pupillary changes (sluggish —> nonreactive, potentially dilated), decreased LOC, abnormal posturing, and respiratory changes

Key point:

  • LIFE-THREATENING EMERGENCY

  • brainstem compression can lead to respiratory and cardiovascular collapse


95
New cards

Assessment of brain injuries

Glasgow coma scale:

  • assesses eye, verbal, motor, responses

  • total score ranges 3-15

    • severity:

      • Mild: GCS 13-15 —> minor injury

      • Moderate: GCS 9-12 —> moderate injury

      • Severe: GCS ≤ 8 —> coma, needs airway protection

    • Mnemonic:

      • 8 or less = intubate — GCS of 8 or less —> cannot protect airway

Pupillary reflex: checks brainstem function —> unequal or nonreactive pupils may indicate increased ICP or herniation

96
New cards

Mechanisms of TBI

Primary injury: immediate mechanical damage at the time of trauma

  • direct impact (ex. coup/contrecoup)

  • penetrating injury

  • acceleration-deceleration and rotational/shearing forces (ex. diffuse axonal injury)

  • immediate neuronal and glial injury

Secondary injury: evolving cellular and physiologic damage that develops over minutes to days

  • hypoxia

  • ischemia (reduced cerebral perfusion)

  • increased intracranial pressure (increased ICP)

  • inflammation

  • excitotoxicity (excess glutamate)

Key point: primary injury occurs at impact; secondary injury evolves afterward and is the major target of treatment

<p><strong>Primary injury:</strong> immediate mechanical damage at the time of trauma</p><ul><li><p>direct impact (ex. coup/contrecoup)</p></li><li><p>penetrating injury</p></li><li><p>acceleration-deceleration and rotational/shearing forces (ex. diffuse axonal injury)</p></li><li><p>immediate neuronal and glial injury</p></li></ul><p><strong>Secondary injury:</strong> evolving cellular and physiologic damage that develops over minutes to days</p><ul><li><p>hypoxia</p></li><li><p>ischemia (reduced cerebral perfusion)</p></li><li><p>increased intracranial pressure (increased ICP)</p></li><li><p>inflammation</p></li><li><p>excitotoxicity (excess glutamate)</p></li></ul><p><strong>Key point:</strong> primary injury occurs at impact; secondary injury evolves afterward and is the major target of treatment </p>
97
New cards

Types of traumatic brain injury (TBI)

Concussion:

  • presentation: transient loss of consciousness (LOC) or confusion

  • mechanism: metabolic (functional) injury; no structural damage

Contusion:

  • definition: focal cortical bruise

  • risk: seizure focus

Axonal shearing:

  • definition: diffuse axonal injury (DAI)

  • result: widespread axonal damage —> coma without gross bleed

Epidural hematoma:

  • source: arterial bleed (middle meningeal artery)

  • course: lucid interval —> rapid decline

Subdural hematoma:

  • source: venous bleed (bridging veins)

  • course: gradual onset; increased risk in elderly or anticoagulated patients

Subarachnoid hemorrhage (SAH):

  • cause: aneurysm rupture

  • presentation: sudden, severe (“thunderclap”) headache; nuchal rigidity

Key point: TBIs differ by mechanism, bleeding source, and clinical pattern — use these key features to recognize the type and guide timely, appropriate care

98
New cards

Skull fractures in neurotrauma

Definition: a break in one or more skull bones from blunt or penetrating head trauma; may be associated with intracranial injury

Common types:

  • linear: simple fracture line —> often stable; assess for underlying brain injury

  • depressed: bone pushed inward —> possible brain injury; may require surgical evaluation

  • basilar: fracture at skull base (anterior, middle, or posterior fossa) —> higher risk for CSF leak and infection

  • open (compound): break in skin or sinuses —> communication with external environment; increased risk for infection

Basilar skull fracture: Red flags:

  • periorbital ecchymosis —> “raccoon eyes”

  • mastoid ecchymosis —> battle sign

  • hemotympanum

  • clear rhinorrhea/otorrhea —> possible CSF leak

Nursing priorities:

  • report suspected basilar skull fracture (with aforementioned findings)

  • avoid blind nasal intubation (ex. NG tube, nasotracheal suctioning)

  • monitor for intracranial injury and infection (ex. meningitis)

Key point: if a basilar skull fracture is suspected, do NOT insert anything into the nose (ex. NG tube) and notify the provider immediately

99
New cards

Skull fractures: diagnostics & monitoring

CT head: first-line for acute blled or fracture

MRI: sensitive for DAI, posterior fossa lesions

EVD (external ventricular drain): measures/monitors ICP + drains CSF to relieve pressure

- avoid lumbar puncture if increased ICP (risk of herniation)

- trend neuro exams and pupil reactivity

100
New cards

Subarachnoid hemorrhage (SAH) management

Etiologies: aneurysmal (ruptured aneurysm) or traumatic (head injury)

Goals: secure aneurysm, prevent rebleeding, and maintain cerebral perfusion

Before treatment: monitor BP; avoid severe hypertension, hypotension, and large fluctuations

Nimodipine: start early; maintain euvolemia

Complications: delayed cerebral ischemia (days 4-14), hydrocephalus, and hyponatremia

Seizures: antiseizure prophylaxis only for selected high-risk patients; treat new-onset seizures promptly

Key point: prevent rebleeding and complications by controlling BP (individualized), giving nimodipine early, and monitoring for delayed cerebral ischemia (days 4-14)